sg299
Generic: CD8-targeted fusosome
sg299: developed by 1 company. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Sana Biotechnology, Inc. (SANA) | Preclinical |
Get deeper analysis on sg299
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis